Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NYSE:CATX NYSE:INFU NASDAQ:IVTY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.37+0.4%$6.74$5.81▼$14.38$609.34M0.83397,369 shs356,879 shsCATXPerspective Therapeutics$3.61-7.4%$3.76$1.60▼$16.55$289.49M1.17949,022 shs647,645 shsINFUInfuSystem$9.63+1.0%$6.44$4.61▼$9.97$196.70M1.81166,097 shs267,781 shsIVTYInvuity$7.39$0.00$2.35▼$9.55N/AN/A324,995 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+6.50%+13.56%+8.54%-7.88%CATXPerspective Therapeutics0.00%-1.90%-12.59%+37.26%-72.94%INFUInfuSystem0.00%+9.06%+78.00%+56.59%+39.57%IVTYInvuity0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.219 of 5 stars3.40.00.00.02.63.31.3CATXPerspective Therapeutics1.6967 of 5 stars3.61.00.00.02.60.80.0INFUInfuSystem3.4409 of 5 stars2.05.00.00.02.64.21.9IVTYInvuityN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.7586.57% UpsideCATXPerspective Therapeutics 3.18Buy$12.56247.80% UpsideINFUInfuSystem 4.00Strong Buy$12.5029.80% UpsideIVTYInvuity 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IVTY, BVS, CATX, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$564.14M1.08$0.59 per share12.58$2.80 per share2.63CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AINFUInfuSystem$139.89M1.41$0.75 per share12.79$2.47 per share3.90IVTYInvuityN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23MN/AN/A16.02N/A-7.11%15.61%4.01%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%N/AINFUInfuSystem$870K$0.23160.5331.06N/A1.12%2.78%1.41%N/AIVTYInvuityN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/AIVTYInvuityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99CATXPerspective TherapeuticsN/A9.609.60INFUInfuSystem0.501.981.59IVTYInvuityN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%CATXPerspective Therapeutics54.66%INFUInfuSystem71.13%IVTYInvuity55.34%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%CATXPerspective Therapeutics3.72%INFUInfuSystem11.40%IVTYInvuity8.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableIVTYInvuityN/AN/AN/ANot OptionableIVTY, BVS, CATX, and INFU HeadlinesRecent News About These CompaniesIvy Bank Review: Solid High-Interest SavingsNovember 1, 2024 | fool.comHow To Spot Poison Ivy In Your Yard And How To Safely Get Rid Of ItSeptember 25, 2024 | forbes.comDelaware Ivy Large Cap Growth Fund ASeptember 11, 2024 | morningstar.comMCLPS Inc (CLPS)August 31, 2024 | investing.comInvuity Announces Results of New PhotonBlade® Studies at 2018 Heart Rhythm Society ConferenceAugust 16, 2024 | br.advfn.comBeyoncé's daughter Blue Ivy attracts praise from famous family with dynamite videoAugust 13, 2024 | hellomagazine.comHBruce A Cleveland's Net WorthAugust 1, 2024 | benzinga.comWhat Is Poison Ivy?April 15, 2024 | health.comHIvy ParsonsApril 9, 2024 | virginislandsdailynews.comVHeartbreak in New York: Penn women's basketball bows out of Ivy Madness tournament with loss to Princeton in the semifinalsMarch 24, 2024 | thedp.comTMen’s basketball’s Clark Slajchert earns All-Ivy second team nodMarch 20, 2024 | thedp.comTPenn baseball voted unanimous #1 in Ivy League preseason pollFebruary 23, 2024 | thedp.comTTop law firm rescinds job offers to Ivy League students who signed letter blaming Israel for violenceOctober 28, 2023 | foxnews.comIvy Queen receives Billboard Icon Award, reflects on difficult road to reggaeton successOctober 23, 2023 | usatoday.comKelly Rowland says she's 'very proud' of Blue Ivy amid performance's for Beyoncé's tourSeptember 27, 2023 | usatoday.comAllergic Contact Dermatitis: Poison IvySeptember 21, 2023 | medscape.comMSeven Life Lessons From Beyoncé And Blue Ivy's Whirlwind Renaissance TourAugust 26, 2023 | theroot.comTThis top college consultant gets students into the Ivy League for $1.5K per hourAugust 16, 2023 | nypost.comNStudy: Ivy League Colleges Aren’t Worth ItAugust 9, 2023 | thestreet.comBeyoncé and Blue Ivy Just Twinned in Matching Sequined Jerseys and Y2K CamoAugust 8, 2023 | instyle.comINew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVTY, BVS, CATX, and INFU Company DescriptionsBioventus NYSE:BVS$7.37 +0.03 (+0.41%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$7.36 0.00 (-0.07%) As of 08/15/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Perspective Therapeutics NYSE:CATX$3.61 -0.29 (-7.44%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.66 +0.05 (+1.41%) As of 08/15/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.InfuSystem NYSE:INFU$9.63 +0.10 (+1.05%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$9.45 -0.18 (-1.86%) As of 08/15/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Invuity NASDAQ:IVTYInvuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access